Managed Care In Europe: Threat Or Opportunity?

9 October 1994

Without exception, governments in Europe are struggling to meet their health care responsibilities due to a number of driving forces which will increase, rather than recede, within the next decade, according to a new report from PROMAR International, entitled Managed Care in Europe: Myth or Reality, Threat or Opportunity?

Firstly, the well-known phenomenon of an aging population is putting a great deal of strain on health care systems. Although this is partly caused by falling birth rates, a significant contributor to this phenomenon is past medical advancement, which means that fewer people now die of illnesses which strike quickly, and more are living longer and eventually dying of prolonged illness for which there is still no cure.

The impact of this trend on health care systems is clearly significant, since it results in a far higher demand for longer periods of care and more complex, expensive treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight